Your browser doesn't support javascript.
loading
Increased frequency and mortality in persons with neurological disorders during COVID-19.
Marsters, Candace M; Bakal, Jeffrey A; Lam, Grace Y; McAlister, Finlay A; Power, Christopher.
Afiliação
  • Marsters CM; Division of Neurology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada.
  • Bakal JA; Division of Neurology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada.
  • Lam GY; Provincial Research Data Services-Alberta Health Services, Edmonton, AB T6G 2B7, Canada.
  • McAlister FA; Alberta Strategy for Patient Oriented Research Unit, Edmonton, AB T6G 2C8, Canada.
  • Power C; Division of Pulmonology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada.
Brain ; 147(7): 2542-2551, 2024 Jul 05.
Article em En | MEDLINE | ID: mdl-38641563
ABSTRACT
Determining the frequency and outcomes of neurological disorders associated with coronavirus disease 2019 (COVID-19) is imperative for understanding risks and for recognition of emerging neurological disorders. We investigated the susceptibility and impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among persons with premorbid neurological disorders, in addition to the post-infection incidence of neurological sequelae, in a case-control population-based cohort. Using health service data collected between 1 March 2020 and 30 June 2021, we constructed a cohort of SARS-CoV-2 RNA-positive (n = 177 892) and -negative (n = 177 800) adults who were age, sex and comorbidity matched and underwent RT-PCR testing at similar times. COVID-19-associated mortality rates were examined within the cohort. Neurological sequelae were analysed during the acute (<3 months) and the post-acute (3-9 months) phases post-infection. The risk of death was significantly greater in the SARS-CoV-2 RNA-positive (2140 per 100 000 person years) compared with RNA-negative (922 per 100 000 person years) over a follow-up of 9 months, particularly amongst those with premorbid neurological disorders adjusted odds ratios (95% confidence interval) in persons with a prior history of parkinsonism, 1.65 (1.15-2.37); dementia, 1.30 (1.11-1.52); seizures, 1.91 (1.26-2.87); encephalopathy, 1.82 (1.02-3.23); and stroke, 1.74 (1.05-2.86). There was also a significantly increased risk for diagnosis of new neurological sequelae during the acute time phase after COVID-19, including encephalopathy, 2.0 (1.10-3.64); dementia, 1.36 (1.07-1.73); seizure, 1.77 (1.22-2.56); and brain fog, 1.96 (1.20-3.20). These risks persisted into the post-acute phase after COVID-19, during which inflammatory myopathy (2.57, 1.07-6.15) and coma (1.87, 1.22-2.87) also became significantly increased. Thus, persons with SARS-CoV-2 infection and premorbid neurological disorders are at greater risk of death, and SARS-CoV-2 infection was complicated by increased risk of new-onset neurological disorders in both the acute and post-acute phases of COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Doenças do Sistema Nervoso Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Doenças do Sistema Nervoso Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá